UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 5, 2022, Thomas F. Kearns, Jr. notified us of his resignation from the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) effective June 16, 2022. Mr. Kearns' resignation as a director is not the result of any disagreement with FibroGen on any matter relating to FibroGen’s operations, policies or practices.
Mr. Kearns joined FibroGen’s Board in November 1996 and served in a number of capacities during his tenure, including as Chairperson of the Board, Lead Independent Director, Chairperson of the Compensation Committee, the Nominating and Corporate Governance Committee and the Finance Committee, and as a member of the Audit Committee. FibroGen is extremely grateful for his service over the past 25 years and wishes him the best in his future endeavors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
FIBROGEN, INC. |
|
|
|
|
Date: |
June 8, 2022 |
By: |
/s/ Michael Lowenstein |
|
|
|
Michael Lowenstein |
Document And Entity Information |
Jun. 05, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jun. 05, 2022 |
Entity Registrant Name | FIBROGEN, INC. |
Entity Central Index Key | 0000921299 |
Entity Emerging Growth Company | false |
Entity File Number | 001-36740 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 77-0357827 |
Entity Address, Address Line One | 409 Illinois Street |
Entity Address, City or Town | San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94158 |
City Area Code | 415 |
Local Phone Number | 978-1200 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.01 par value |
Trading Symbol | FGEN |
Security Exchange Name | NASDAQ |
Q M?D<8_0=02P,$% @ QX#(5)^@&_"Q @ X@P T
M !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV
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MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5RHY_U=3_ 102P,$% @ QX#(5)>*
MNQS $P( L !?